NextCure
NXTC
71 hedge funds and large institutions have $99.5M invested in NextCure in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 20 increasing their positions, 28 reducing their positions, and 13 closing their positions.
113% more call options, than puts
Call options by funds: $627K | Put options by funds: $295K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
0.22% less ownership
Funds ownership: 4.67% → 4.45% (-0.22%)
9% less funds holding
Funds holding: 78 → 71 (-7)
18% less capital invested
Capital invested by funds: $122M → $99.5M (-$22.4M)
29% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 28
54% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$3.18M |
| 2 |
Millennium Management
New York
|
+$1.34M |
| 3 |
Renaissance Technologies
New York
|
+$1.27M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$976K |
| 5 |
Two Sigma Advisers
New York
|
+$757K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CPX
Canaan Partners X
Menlo Park,
California
|
-$3.78M |
| 2 |
Morgan Stanley
New York
|
-$3.08M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.3M |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$1.84M |
| 5 |
SG Americas Securities
New York
|
-$764K |
NXTC Hedge Fund Activity: Q3 2021 in Review
71 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in NextCure (NXTC) for Q3 2021, worth a combined $99.5M — down 18% from $122M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of NXTC and 6 opened new positions — a net loss of 7 holders — while 28 trimmed existing stakes and 20 added.
The largest buyer was Silverarc Capital Management, adding an estimated $3.18M. The largest seller was Canaan Partners X, cutting an estimated $3.78M.
- 71 institutional investors held NextCure (NXTC) as of Q3 2021, down from 78 in Q2 2021.
- Funds reported $99.5M of NextCure stock for Q3 2021, down 18% quarter-over-quarter.
- 6 funds opened new NextCure positions in Q3 2021 and 13 closed out, a net change of -7 holders.
- The largest NextCure buyer in Q3 2021 was Silverarc Capital Management, an estimated $3.18M added.
- The largest NextCure seller in Q3 2021 was Canaan Partners X, an estimated $3.78M sold.
Based on aggregated 13F filings for Q3 2021.